These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 29505847)

  • 1. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET.
    Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS
    J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-catenin deficiency in hepatocytes aggravates hepatocarcinogenesis driven by oncogenic β-catenin and MET.
    Liang Y; Feng Y; Zong M; Wei XF; Lee J; Feng Y; Li H; Yang GS; Wu ZJ; Fu XD; Feng GS
    Hepatology; 2018 May; 67(5):1807-1822. PubMed ID: 29152756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell transcriptomics reveals opposing roles of Shp2 in Myc-driven liver tumor cells and microenvironment.
    Chen WS; Liang Y; Zong M; Liu JJ; Kaneko K; Hanley KL; Zhang K; Feng GS
    Cell Rep; 2021 Nov; 37(6):109974. PubMed ID: 34758313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.
    Shang N; Arteaga M; Zaidi A; Stauffer J; Cotler SJ; Zeleznik-Le NJ; Zhang J; Qiu W
    Hepatology; 2015 Jan; 61(1):214-26. PubMed ID: 25163657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.
    Luo X; Liao R; Hanley KL; Zhu HH; Malo KN; Hernandez C; Wei X; Varki NM; Alderson N; Chu C; Li S; Fan J; Loomba R; Qiu SJ; Feng GS
    Cell Rep; 2016 Dec; 17(11):2979-2993. PubMed ID: 27974211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical SH2 domain-containing protein tyrosine phosphatase 2 inhibition suppresses primary and metastasized liver tumors by provoking hepatic innate immunity.
    Liu JJ; Xin B; Du L; Chen L; Long Y; Feng GS
    Hepatology; 2023 May; 77(5):1512-1526. PubMed ID: 35503714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
    Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
    Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice.
    Qiao Y; Xu M; Tao J; Che L; Cigliano A; Monga SP; Calvisi DF; Chen X
    BMC Cancer; 2018 Nov; 18(1):1093. PubMed ID: 30419856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor promotion and inhibition by phenobarbital in livers of conditional Apc-deficient mice.
    Braeuning A; Gavrilov A; Geissler M; Wenz C; Colnot S; Templin MF; Metzger U; Römer M; Zell A; Schwarz M
    Arch Toxicol; 2016 Jun; 90(6):1481-94. PubMed ID: 26838046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
    Martin E; Agazie YM
    Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant activation of hepatocyte growth factor/MET signaling promotes β-catenin-mediated prostatic tumorigenesis.
    Aldahl J; Mi J; Pineda A; Kim WK; Olson A; Hooker E; He Y; Yu EJ; Le V; Lee DH; Geradts J; Sun Z
    J Biol Chem; 2020 Jan; 295(2):631-644. PubMed ID: 31819003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1.
    Yang L; Inokuchi S; Roh YS; Song J; Loomba R; Park EJ; Seki E
    Gastroenterology; 2013 May; 144(5):1042-1054.e4. PubMed ID: 23391818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.
    Nisa L; Häfliger P; Poliaková M; Giger R; Francica P; Aebersold DM; Charles RP; Zimmer Y; Medová M
    Mol Cancer; 2017 May; 16(1):93. PubMed ID: 28532501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice.
    Awuah PK; Rhieu BH; Singh S; Misse A; Monga SP
    PLoS One; 2012; 7(6):e39771. PubMed ID: 22761897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis.
    Patil MA; Lee SA; Macias E; Lam ET; Xu C; Jones KD; Ho C; Rodriguez-Puebla M; Chen X
    Cancer Res; 2009 Jan; 69(1):253-61. PubMed ID: 19118010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.